Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).
- Sponsor
- TNC Nutrición Terapéutica S.L.
- Study ID
- NCT07406789
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Advanced Breast Cancer
- Gynecologic Cancers
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Personalised dietary intervention. — DIETARY_SUPPLEMENTPersonalised dietary intervention, tailored to clinical and metabolic parameters and individual preferences.
- General recommendations — BEHAVIORALGeneral recommendations on the Mediterranean diet, without active dietary intervention.
Study Details
The objective of the study is to evaluate the effect of a personalized dietary intervention (cohort A), compared with a standard nutritional intervention based on general recommendations for following a Mediterranean diet (cohort B), in women with advanced solid tumors of gynecologic or breast origin who are receiving treatment with antibody-drug conjugates (ADCs). This intervention is exclusively nutritional and does not involve the use of any investigational drug.
Key Dates
- First listed
- Feb 12, 2026
- Start date
- Feb 11, 2026
- Status verified
- Feb 2026
- Primary completion
- Feb 11, 2028
- Completion
- Feb 11, 2028
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Cohort A (intervention)Personalised dietary intervention, tailored to clinical and metabolic parameters and individual preferences.
- Active Comparator: Cohort B (Control)General recommendations on the Mediterranean diet, without active dietary intervention.
Primary Outcome Measure
Evaluate the effect of a personalized dietary intervention on health-related quality of life (HRQoL), compared with general recommendations for a Mediterranean diet, in women with advanced gynecologic or breast tumors treated with ADCs. [ Time Frame: 24 months ]
Central Contacts
- TNC Nutrición Terapéutica S.L+34 672 567 899
Related Studies
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesRecruiting · Stanford University · Stanford, California
- Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsPHASE1 · Recruiting · National Cancer Institute (NCI) · Fairway, Kansas
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPHASE1 · Recruiting · Relay Therapeutics, Inc. · Tucson, Arizona
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorPHASE2 · Recruiting · Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire